Apologies Sillazze I obviously missed a key part of your message.
Based on my limited understanding of the field, I find it difficult to see what connection there might be between the recent increase in interest in developing RNA and gene therapies for Rett syndrome and Neuren’s trial of NNZ-2591 in Prader Willi syndrome.
The only type of connection I can see is between the Prader-Willi and Angelman syndrome programs insofar as both syndromes are caused by the same chromosomal deletion on 15q11.2-q13.
RNA-based+2591PW, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B | |||
| Open | High | Low | Value | Volume |
| $20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 782 | $20.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 1021 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |